Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis

Published on 02 Jan 2019
Last Updated on 02 Jan 2019

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended listing nintedanib or pirfenidone on the Medication Assistance Fund (MAF) for treating idiopathic pulmonary fibrosis, because of limited clinical benefits and unacceptable cost-effectiveness compared with best supportive care at the prices proposed by the manufacturers.

Nintedanib and pirfenidone for IPF (2 Jan 2019) [PDF, 482 KB]

Anti-fibrotics for IPF Plain English Summary (2 Jan 2019) [PDF, 529 KB]